Derma Sciences (DSCI) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Piper Jaffray Cuts Price Target on Derma Sciences (DSCI) Following Mixed 3Q Results
November 10, 2015 9:33 AM ESTPiper Jaffray reiterated a Neutral rating on Derma Sciences (NASDAQ: DSCI), and cut the price target to $6.00 (from $7.00), following the company's 3Q earnings report. Derma Sciences reported net earnings per share of ($0.35), beating consensus of ($0.43), on revenues of $22M (vs. Street's 22.31M).
Analyst David Amsellem... More
